Shopping Cart
- Remove All
- Your shopping cart is currently empty
DA 3003-2, a selectively potent Cdc25 inhibitor, exhibits antiproliferative activity and holds potential for prostate cancer research. It induces cell cycle arrest at the G2/M phase and increases the expression of P-tyr 15 Cdc2.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $155 | 35 days | |
5 mg | $675 | 35 days | |
10 mg | $1,190 | 35 days | |
25 mg | $2,410 | 35 days |
Description | DA 3003-2, a selectively potent Cdc25 inhibitor, exhibits antiproliferative activity and holds potential for prostate cancer research. It induces cell cycle arrest at the G2/M phase and increases the expression of P-tyr 15 Cdc2. |
In vivo | Pentigetide (1 mg ; four times daily)-treated patients showed a statistically significant greater reduction in the frequency (P = .004) and severity (P = .05) of total nasal symptom score (sneezing, nasal congestion, and rhinorrhea) and in the individual nasal symptom scores compared with placebo-treated patients.[1] |
Alias | NSC663285 |
Molecular Weight | 321.76 |
Formula | C15H16ClN3O3 |
Cas No. | 383907-47-9 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.